Navigation Links
China Sky One Medical, Inc. Announces Record First Quarter 2008 Results
Date:5/13/2008

en examined by experts in the field and has been submitted to the SDFA for approval. The Company is responsible for all the research expenses and holds the patent for the device.

Business Outlook

"Thus far in 2008, we have completed two acquisitions, including one which will enhance our product portfolio and pipeline of new drugs and another which will allow us to quickly expand sales of our medicinal products. In 2008, we expect strong growth in all of our product categories, with sales of bio- chemical products and our highly successful Slim Patch making the largest contributions," said Mr. Liu. "For the full year 2008, and as a result of our recent acquisitions, we are currently on track to increase revenues materially as compared to last year and hope to increase our gross margin to approximately 78.5%."

Conference Call

The Company will conduct a conference call at 5:00 p.m. Eastern Time on Thursday, May 15, 2008 to discuss the first quarter 2008 results. To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: (888)552-2116. International callers should dial (706)634-2457. The Conference ID for this call is 47653429. If you are unable to participate in the call at this time, a replay will be available for fourteen days starting on Thursday, May 15, 2008 at 7:00 p.m. Eastern Time. To access the replay, dial (800)642-1687, international callers dial (706)645-9291, conference ID 47653429.

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is engaged in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science Technology Company, Harbin First Bio-Engineering Company Limited, Heilongjiang Tianlong Pharmaceutical, Inc.,") and Heilongjiang Haina Pharmaceutical Inc., the Company manufactures and d
'/>"/>

SOURCE China Sky One Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. China Medicine Announces Solid First Quarter 2008 Results
2. Tianyin Pharmaceutical to Present at the Brean Murray All-Cap All-China Conference in New York City on May 20, 2008 at 10:15 a.m. EDT
3. China-Biotics, Inc. Completes Foundation for Its New Plant
4. Amnis and Gene Company, Ltd. Announce Agreement to Market ImageStream Technology in China
5. Sinovac to Present at the Brean Murray, Carret & Co. All-Cap All-China Conference and the Roth China Discovery Tour 2008
6. China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results
7. China Biologic Products Announces SFDA Approval for the Production of Cryoprecipitate and for the Clinical Trial of Human Prothrombin Complex
8. DuPont Partnering with China to Increase Farm Productivity
9. China Yingxia International, Inc. Acquires Grocery Chain and Online Distribution Network
10. China Sky One Medical, Inc. Acquires Heilongjiang Haina Pharmaceutical Inc.
11. Syngenta To Build Major Global Biotech Research Center in Beijing, China
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Alberta companies delivering new products to the health & medical marketplace 2JourneyLite of Houston Now Offering Sleeve Gastrectomy 2
Breaking Biology News(10 mins):$2.4 million stimulus fuels effort to regenerate injured spinal cords 2$2.4 million stimulus fuels effort to regenerate injured spinal cords 3$2.4 million stimulus fuels effort to regenerate injured spinal cords 4Springer signs co-publishing agreement with the Royal Swedish Academy of Sciences 2List of 'unsung' wildlife affected by climate change released 2XRC Medical Imaging Announces Rapid Test Results 14182 1XRC Medical Imaging Announces Rapid Test Results 14182 2Abbotts XIENCE V 28R 29 Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long Term Safety Results in SPIRIT III Trial 5024 1Abbotts XIENCE V 28R 29 Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long Term Safety Results in SPIRIT III Trial 5024 2Abbotts XIENCE V 28R 29 Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long Term Safety Results in SPIRIT III Trial 5024 3Abbotts XIENCE V 28R 29 Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long Term Safety Results in SPIRIT III Trial 5024 4Abbotts XIENCE V 28R 29 Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long Term Safety Results in SPIRIT III Trial 5024 5Abbotts XIENCE V 28R 29 Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long Term Safety Results in SPIRIT III Trial 5024 6Dalton Pharma Services Adds Formulation Development Services 57793 1Dalton Pharma Services Adds Formulation Development Services 57793 2